IDFC CORE EQUITY FUND

IDFC CORE EQUITY FUND

(Previously known as IDFC Classic Equity Fund w.e.f. May 28, 2018) Large & Mid Cap Fund - An open ended equity scheme investing in both large cap and mid cap stocks

IDFC Core Equity Fund is a diversified equity fund with a large & mid cap bias currently. The focus of the fund is to build a portfolio of Quality companies while being cognizant of the relative valuation.

     FUND PHILOSOPHY*

The fund builds a portfolio of quality stocks with lower relative valuations. Quality (for non-financial stocks) is ascribed on three fronts – conversion of EBIDTA to operating cash – OCF as % of EBIDTA > 33%; Moderate leverage: Debt/EBIDTA <3x; Profitability: EBIDTA / Net operating Assets >30%. Companies that qualify on these three parameters and those which are relatively cheaper within a peer group on P/B basis form part of the ‘quality’ universe. Roughly 50% of the portfolio will comprise of such quality companies; ~30% would be for financial sector and balance 20% would be invested in benchmark heavyweights and themes, which we expect to play out over next 6/12 months. On a tactical basis, the fund may take a part of its overall holding through near month stock futures.

      OUTLOOK

• With the spread of the pandemic and the lockdown during Q1 FY21, earnings for the year FY21 were sharply downgraded.

• However, the swifter than expected economic recovery led to a more robust Q2 FY21.

• Upgrades exceeded downgrades 3x, a rarity, after years of earnings disappointment.

• FY21 estimates, quickly rebounded from negative to positive territory, despite the Q1 debacle.

• The fall during Mar’20 lasted less than 35 trading days, erasing between 36-43% across the indices – Large, Mid and Small Caps. Supportive action from Central Banks was quicker.

• As investors searched for stable earnings, rotation from one sector to another, as exhibited from Apr-Dec’20 phase was evident.

• Staples after outperforming in Mar-Apr, have underperformed since then. Pharma and IT services outperformed during May-Sept; Banks/NBFC, after underperforming from Mar-Sept,20; outperformed during Oct-Dec’20.

• After the debacle of Mar’20, Small caps outshone the rest of the market – for the first time since CY17.

• If economic recovery is robust and RBI does not move aggressively into high real interest zone, Small caps could benefit the most.

     FUND FEATURES: (Data as on 31st December'20)

Category: Large & Mid Cap
Monthly Avg AUM: Rs2,199.75 Crores
Inception Date: 9th August 2005
Fund Manager: Mr. Anoop Bhaskar (w.e.f. 30/04/2016)
Benchmark: LargeMidcap 250 TRI (w.e.f. 7th October 2019)
Minimum Investment Amount: Rs5,000/- and any amount thereafter.
Exit Load: If redeemed/switched out within 365 days from the date of allotment:
➧ Upto 10% of investment:Nil,
➧ For remaining investment: 1% of applicable NAV.
If redeemed / switched out after 365 days from date of allotment: Nil. (w.e.f. May 08, 2020)
SIP Frequency Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)
Options Available: Growth, Dividend - (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))
Other Parameters:
Beta: 0.98
R Square: 0.98
Standard Deviation (Annualized): 23.94%

PLANDIVIDEND
RECORD DATE
₹/UNIT NAVNAV
REGULAR 16-Mar-20 1.03 12.0100
14-Mar-19 0.80 15.4200
12-Mar-18 1.01 16.4254
DIRECT 16-Mar-20 0.39 13.7900
14-Mar-19 0.90 17.4700
12-Mar-18 1.13 18.3717
Face Value per Unit (in ₹) is 10
Dividend is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of dividend, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

PORTFOLIO (31 December 2020)

Name of the Instrument % of NAV
Equity and Equity related Instruments 99.31%
Banks 19.73%
ICICI Bank 6.67%
HDFC Bank 6.00%
Axis Bank 2.00%
State Bank of India 1.79%
The Federal Bank 1.01%
Kotak Mahindra Bank 1.00%
RBL Bank 0.95%
The Federal Bank - Equity Futures 0.22%
RBL Bank - Equity Futures 0.10%
Pharmaceuticals 12.81%
IPCA Laboratories 2.89%
Cadila Healthcare 2.02%
Dr. Reddy's Laboratories 1.87%
Sun Pharmaceutical Industries 1.65%
Aurobindo Pharma 1.13%
Alkem Laboratories 1.13%
Alembic Pharmaceuticals 0.76%
Lupin 0.71%
Indoco Remedies 0.66%
Software 12.68%
Infosys 7.40%
Mastek 1.48%
Birlasoft 1.45%
HCL Technologies 0.94%
MphasiS 0.81%
KPIT Technologies 0.39%
Infosys - Equity Futures 0.21%
Industrial Products 6.76%
AIA Engineering 2.05%
Supreme Industries 1.91%
Bharat Forge 1.19%
Cummins India 0.82%
EPL 0.79%
Auto Ancillaries 6.08%
MRF 2.30%
Apollo Tyres 1.53%
Bosch 0.77%
Balkrishna Industries 0.67%
Minda Industries 0.53%
Asahi India Glass 0.23%
Bosch - Equity Futures 0.05%
Cement 5.79%
ACC 2.42%
The Ramco Cements 1.69%
Name of the Instrument % of NAV
Ambuja Cements 1.68%
Consumer Non Durables 4.12%
Emami 1.24%
Marico 1.23%
Tata Consumer Products 0.84%
ITC 0.81%
Petroleum Products 3.73%
Reliance Industries 2.43%
Bharat Petroleum Corporation 1.30%
Power 3.48%
Torrent Power 1.75%
Kalpataru Power Transmission 1.11%
Nava Bharat Ventures 0.62%
Construction Project 3.35%
Larsen & Toubro 1.81%
KEC International 1.33%
Larsen & Toubro - Equity Futures 0.21%
Finance 3.28%
ICICI Securities 2.11%
Mas Financial Services 0.77%
Sundaram Finance 0.40%
Telecom - Services 2.94%
Bharti Airtel 2.94%
Gas 2.64%
Mahanagar Gas 1.58%
Gujarat State Petronet 1.06%
Consumer Durables 2.34%
Crompton Greaves Consumer Electricals 1.20%
Voltas 1.14%
Chemicals 2.14%
Deepak Nitrite 2.14%
Hotels/ Resorts and Other Recreational Activities 2.05%
The Indian Hotels Company 2.05%
Ferrous Metals 2.05%
Jindal Steel & Power 2.05%
Auto 1.83%
Mahindra & Mahindra 1.83%
Retailing 1.50%
Aditya Birla Fashion and Retail 1.50%
Preference Shares 0.005%
Media & Entertainment 0.005%
Zee Entertainment Enterprises 0.005%
Net Cash and Cash Equivalent 0.69%
Grand Total 100.00%

     SECTOR ALLOCATION

     RISKOMETER

This product is suitable for investors who are seeking*:
• To create wealth over long term
• Investment predominantly in equity and equity related instruments in large and mid-cap companies
*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.


^The benchmark of the fund has been revised from S&P BSE 200 TRI to Nifty LargeMidcap 250 TRI w.e.f. 7th October 2019
Ratios calculated on the basis of 3 years history of monthly data.
The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad parameters of Scheme Information Document.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

Contact your Financial Advisor
Call toll free 1800-2-6666-88

Contact your Financial Advisor

Call toll free
1800-2-6666-88

Invest online at www.idfcmf.com

www.facebook.com/idfcamc

@IDFCMF